Ovagen

Ovagen is a Khavinson-class peptide bioregulator derived from ovarian tissue, developed through Vladimir Khavinson's systematic organ-specific bioregulator research program at the St. Petersburg Institute of Bioregulation and Gerontology, and proposed to restore gene expression and physiological function in aging ovarian tissue by interacting with chromatin regulatory elements in target cells. As an ovarian tissue-derived bioregulator, Ovagen is positioned within the Khavinson framework as a compound designed to modulate transcription in Leydig and granulosa cells, potentially influencing estrogen synthesis, follicular function, and reproductive aging; the class-level mechanistic research has characterized how short Khavinson peptides bind DNA regulatory sequences to activate tissue-specific gene expression programs. Published research on the Khavinson peptide bioregulator class as a whole documents the systematic discovery and characterization of organ-specific peptides, with class-level evidence from animal models and human observational studies demonstrating restorative effects on tissue-specific physiological parameters across multiple organ systems. Ovagen has no FDA approval and no approved indication in any Western jurisdiction; no indexed PubMed studies specifically characterize ovagen's clinical outcomes in human subjects, and the compound is available only through the Russian bioregulator market under the class-level evidence framework established by the Khavinson group's published research.